- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01386294
Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection
A Phase III, Multi-Centre, Randomized Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir Gel in the Prevention of Human Immunodeficiency Virus Type 1 Infection in Women, and to Examine Effects of the Microbicide on the Incidence of Herpes Simplex Virus Type 2 Infection
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a phase III, multicenter trial to assess the safety and effectiveness of 1% tenofovir gel, administered vaginally by approximately 2900 sexually active women at high risk for sexually transmitted HIV. Approximately 2600 women aged 18-30 years old will be enrolled to achieve the required number of endpoints to show an effect on HIV-1 infection, while up to 300 additional women aged 31-40 years old will be enrolled to collect more safety information in this age group.
This is an event driven study that plans to randomize seronegative women. Participants will be randomized to a 1:1 ratio to receive 1% tenofovir gel or placebo gel. Each will be asked to insert a dose of the assigned study product within 12 hours prior to a coital event and another dose as soon as possible within 12 hours after a coital event. Participants will be advised to use only two doses of gel in a 24 hour period.
All women will be evaluated for the rates of adverse events and the rate of HIV seroconversion. In addition, the study will evaluate several secondary endpoints that bear directly on potential risks and benefits of vaginal tenofovir gel use.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Cape Town, Sydafrika
- Desmond Tutu HIV Centre / University of Cape Town
-
Diepkloof, Sydafrika
- Perinatal HIV Research Unit / University of the Witwatersrand
-
Hillbrow, Sydafrika
- Wits Reproductive Health and HIV Institute / University of the Witwatersrand
-
Ladysmith, Sydafrika, 3370
- Qhakaza Mbokodo Research Clinic
-
Pretoria, Sydafrika
- Medunsa Clinical Research Unit / Ga-Ra
-
Rustenburg, Sydafrika
- The Aurum Institute (Rustenburg)
-
Soshanguve, Sydafrika
- Setshaba Research Centre
-
Tembisa, Sydafrika
- The Aurum Institute, Tembisa Hospital
-
-
Kwa-Zulu NAtal
-
Pietermaritzburg, Kwa-Zulu NAtal, Sydafrika, 316
- MatCH Edendale Research Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Confirmed age 18-40 years (inclusive)
- Able and willing to provide written informed consent
- Able and willing to provide adequate locator information for study retention and safety purposes
- Sexually active, defined as having had vaginal intercourse at least twice in the past 30 days prior to screening
- HIV negative on two rapid tests performed by study staff within 30 days of enrolment (see algorithm in Appendix 3).
- No evidence of glycosuria
- No evidence of proteinuria greater than trace*
- No history of pathological bone fractures
- Have a negative pregnancy test
- Women currently breastfeeding may be enrolled in the study
- Agree to use a study-approved effective non-barrier form of contraception
- Agree to adhere to study visits and procedures
- Willing to use study gel as advised
Not using or taking any of the following groups of medications:
- Nephrotoxic agents
- Drugs that slow renal excretion
- Immune system modulators
- Other antiretrovirals
Exclusion Criteria:
- History of adverse reaction to latex.
Plans any of the following during the study period
- To travel away from the study site for more than 30 consecutive days.
- To relocate away from the study site.
- To become pregnant.
- To enrol in any other study of an investigational product or behaviour modification related to HIV prevention.
- If in the opinion of the examining clinician, is not sexually active
- Inadequate renal function (serum creatinine greater than 1.5mg/dl and creatinine clearance less than 50ml/min, as estimated using the method of Cockcroft and Gault96 )
- Grade 3 and above ALT and AST at screening or any clinical sign of liver disease ( e.g. ascites, hepatomegaly, jaundice)
- Abnormal serum phosphate levels (Grade 3 and above)
- Has a clinically apparent finding on speculum pelvic examination (observed by study staff) involving deep epithelial disruption. Otherwise eligible participants with speculum pelvic examination findings involving deep epithelial disruption may proceed with enrolment after the findings have resolved and the inclusion/exclusion are met.
- Received previously or receiving an experimental HIV vaccine
- Currently participating in another HIV prevention intervention study or participation in any other clinical trial with a biomedical intervention in the last six months
- Has current STI symptoms and/or other reproductive tract infection requiring treatment, as assessed by study staff. Otherwise eligible participants diagnosed during screening with infection(s) requiring treatment may be enrolled provided that treatment has been completed.
- Any clinical evidence of untreated cervical abnormalities
- Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Tenofovir 1% vaginal gel
Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
|
Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5.
Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
|
Placebo-jämförare: Universal placebo gel
Participants will be required to insert a single dose of assigned gel intravaginally up to 12 hours before coitus and a second dose within 12 hours after coitus but no more than 2 applications within a 24 hour period.
|
The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide.
Each applicator contains approximately 4ml of placebo gel
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Effectiveness
Tidsram: 30 months
|
Incidence of HIV-1 infection: HIV incidence will be determine by detection of HIV antibodies using two HIV rapid tests (of which one will be FDA approved) according to algorithm in protocol.
One of the rapid tests will detect both HIV-1 and HIV-2; the other will be specific for HIV-1.
All endpoints will be reviewed by an expert committee (the Endpoint Adjudication Committee).
In carrying out this review, the Committee will use guidelines prepared by the protocol committee for this purpose and recorded in the Manual of Procedures
|
30 months
|
Safety
Tidsram: 30 months
|
Grade 2, 3, and 4 clinical and laboratory adverse events as defined by the DAIDS toxicity table
|
30 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Incidence of HSV-2 infection
Tidsram: 30 months
|
HSV-2 status will be established at enrollment according to a testing algorithm in the protocol.
At product discontinuation samples of all those that were HSV-2 seronegative at enrollment will be tested.
To identify and confirm incident HSV-2 infections and the timing of these infections, blood samples that were stored will be tested to determine the earliest equivocal or positive result.
These samples will be then be tested by HSV Western blot.
Samples positive on HSV Western blot will be deemed to be incident HSV-2 infections.
|
30 months
|
Pregnancy
Tidsram: 30 months
|
Incidence of pregnancy loss, prematurity, low birth weight, and major and minor congenital anomalies will be determined
|
30 months
|
Gel and condom use
Tidsram: 30 months
|
30 months
|
|
HIV-1 incidence after product withdrawal
Tidsram: 3 months after product withdrawal
|
HIV testing will be conducted 3 months after product discontinuation and if HIV positive, the last stored sample will be tested to ascertain timing of infection and viral tenofovir resistance testing will be performed
|
3 months after product withdrawal
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Helen Rees, Prof, University of Witwatersrand, South Africa
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hudsjukdomar
- RNA-virusinfektioner
- Virussjukdomar
- Blodburna infektioner
- Smittsamma sjukdomar
- Sexuellt överförbara sjukdomar, virala
- Sexuellt överförbara sjukdomar
- Lentivirusinfektioner
- Retroviridae-infektioner
- Immunologiska bristsyndrom
- Immunsystemets sjukdomar
- DNA-virusinfektioner
- Hudsjukdomar, Smittsamma
- Hudsjukdomar, virala
- Herpesviridae-infektioner
- Långsamma virussjukdomar
- HIV-infektioner
- Infektioner
- Förvärvat immunbristsyndrom
- Herpes simplex
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Omvända transkriptashämmare
- Nukleinsyrasynteshämmare
- Enzyminhibitorer
- Anti-HIV-medel
- Antiretrovirala medel
- Tenofovir
Andra studie-ID-nummer
- FACTS 001
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV-förebyggande
-
Medical College of WisconsinNational Institute of Mental Health (NIMH)AvslutadHIV-prevention och bedömningsreaktivitetSydafrika
-
The Policy & Research GroupDepartment of Health and Human ServicesRekrytering
-
The Policy & Research GroupDepartment of Health and Human Services; Mathematica Policy Research, Inc.Aktiv, inte rekryterandePrevention av tonårsgraviditetFörenta staterna
-
The Policy & Research GroupThe Office of Adolescent Health, HHSAvslutadPrevention av tonårsgraviditet
-
The Policy & Research GroupDepartment of Health and Human ServicesAvslutadPrevention av tonårsgraviditet
-
University of Colorado, DenverAvslutadPrevention av tonårsgraviditetFörenta staterna
-
The Policy & Research GroupDepartment of Health and Human ServicesAvslutad
-
University of New MexicoDepartment of Health and Human ServicesAvslutadPrevention av tonårsgraviditetFörenta staterna
-
Mathematica Policy Research, Inc.Office of Population Affairs; California Department of Public Health, MCAHAvslutadPrevention av tonårsgraviditetFörenta staterna
-
The Policy & Research GroupDepartment of Health and Human ServicesAvslutadPrevention av tonårsgraviditet
Kliniska prövningar på Tenofovir gel
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); National...Avslutad
-
University of WashingtonGilead Sciences; CONRADAvslutadHerpes simplex typ IIFörenta staterna
-
Ian McGowanNational Institute of Allergy and Infectious Diseases (NIAID); CONRADAvslutadHIV-förebyggandeFörenta staterna
-
CONRADEunice Kennedy Shriver National Institute of Child Health and Human Development... och andra samarbetspartnersAvslutadHIV-negativ | Högrisk MSM | 18-30 årFörenta staterna, Puerto Rico
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); National... och andra samarbetspartnersAvslutadHIVFörenta staterna, Sydafrika, Peru, Puerto Rico, Thailand
-
National Institute of Allergy and Infectious Diseases...Avslutad
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID)Avslutad
-
Centre for the AIDS Programme of Research in South...United States Agency for International Development (USAID); FHI 360; CONRADAvslutadHIV-infektionerSydafrika
-
Ian McGowanNational Institute of Allergy and Infectious Diseases (NIAID); CONRADAvslutadHIV-förebyggandeFörenta staterna
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... och andra samarbetspartnersAvslutadFarmakokinetik för 1% Tenofovir Gel efter samlag | Farmakodynamik för 1% Tenofovir Gel efter samlagFörenta staterna